Want to see KR:003850 full AI Analyst Report?
Boryung Corporation (003850) AI Stock Analysis
Boryung Corporation
(Korea Exchange:003850)
The score is driven primarily by solid underlying financial performance (revenue growth, moderate leverage, and positive free cash flow), supported by favorable valuation (low P/E and a dividend). These positives are tempered by bearish technical signals (negative MACD and trading below key moving averages) and the fundamental risk of ongoing gross margin compression alongside higher debt.
Boryung Corporation (003850) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- KRW 699.09B
- Dividend Yield
- 1.93%
- Average Volume (3M)
- 94.79K
- Price to Earnings (P/E)
- 9.5
- Beta (1Y)
- 0.23
- Revenue Growth
- 6.39%
- EPS Growth
- 29.21%
- Country
- KR
- Employees
- 1,645
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Pharmaceuticals
Boryung Corporation Business Overview & Revenue Model
Company Description
Boryung Corporation engages in the manufacture and sale of pharmaceutical products in South Korea and internationally. It offers prescription drugs for hypertension, dyslipidemia, and diabetes drugs. The company was formerly known as Boryung Pharmace...
Boryung Corporation Financial Statement Overview
Summary
Healthy multi-year revenue expansion with steady operating profitability and currently positive free cash flow. Offsetting this, gross margin has compressed materially into the mid‑20% range (TTM) and debt has stepped up versus 2024, while cash flow has been volatile year-to-year.
Income Statement
74PositiveBalance Sheet
70PositiveCash Flow
67Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.06T | 1.02T | 1.02T | 859.63B | 760.48B | 627.28B |
| Gross Profit | 365.26B | 352.49B | 363.36B | 353.43B | 307.19B | 264.94B |
| EBITDA | 137.18B | 108.59B | 114.81B | 110.24B | 106.80B | 81.82B |
| Net Income | 120.58B | 64.30B | 69.63B | 40.20B | 41.89B | 43.04B |
Balance Sheet | ||||||
| Total Assets | 1.53T | 1.41T | 1.16T | 915.51B | 892.39B | 828.64B |
| Cash, Cash Equivalents and Short-Term Investments | 135.03B | 254.68B | 191.85B | 20.05B | 17.92B | 201.44B |
| Total Debt | 388.86B | 330.02B | 168.61B | 204.22B | 208.25B | 215.50B |
| Total Liabilities | 635.65B | 567.56B | 379.58B | 366.26B | 375.97B | 354.33B |
| Stockholders Equity | 894.81B | 845.50B | 784.50B | 548.75B | 515.92B | 473.86B |
Cash Flow | ||||||
| Free Cash Flow | 124.80B | 111.74B | 60.51B | 18.88B | -95.18B | 849.90M |
| Operating Cash Flow | 150.19B | 133.18B | 80.56B | 42.22B | 27.81B | 60.17B |
| Investing Cash Flow | -255.59B | -226.68B | -40.84B | -29.16B | -147.65B | -47.76B |
| Financing Cash Flow | 23.50B | 135.71B | 128.38B | -12.65B | -14.65B | 111.99B |
Boryung Corporation Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KR:003850, the sentiment is Negative. The current price of 8310.00 is below the 20-day moving average (MA) of 8428.50, below the 50-day MA of 8644.80, and below the 200-day MA of 9005.10, indicating a bearish trend. The MACD of -67.44 indicates Negative momentum. The RSI at 43.52 is Neutral, neither overbought nor oversold. The STOCH value of 15.63 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KR:003850.
Boryung Corporation Peers Comparison
Overall Rating
KR:00106071Outperform- KR:00385068Neutral
KR:00309062Neutral
KR:18575057Neutral
KR:00239044Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| KR:001060 | 71Outperform | KRW 555.42B | 5.49 | ― | 2.83% | 10.50% | 96.29% |
| KR:003850 | 68Neutral | KRW 702.03B | 9.47 | ― | 1.93% | 6.39% | 29.21% |
| KR:003090 | 62Neutral | KRW 617.86B | 3.25 | ― | 1.32% | 4.55% | 116.82% |
| KR:185750 | 57Neutral | KRW 831.41B | 10.46 | ― | 0.79% | 7.15% | 29.88% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| KR:002390 | 44Neutral | KRW 113.00B | -10.81 | ― | 2.44% | 7.15% | 59.41% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| KR:003850 | Boryung Corporation | 8310.00 | -461.66 | -5.26% | |
| KR:001060 | JW Pharmaceutical Corporation | 23000.00 | -645.26 | -2.73% | |
| KR:002390 | Handok, Inc. | 8210.00 | -2848.67 | -25.76% | |
| KR:003090 | Daewoong Co., Ltd. | 15110.00 | -6496.22 | -30.07% | |
| KR:086450 | DongKook Pharmaceutical Co., Ltd. | 23450.00 | 6091.61 | 35.09% | |
| KR:185750 | Chong Kun Dang Pharmaceutical Corp. | 63100.00 | -19812.28 | -23.90% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 28, 2026